MX2024009854A - Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genetica rara de la obesidad - Google Patents

Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genetica rara de la obesidad

Info

Publication number
MX2024009854A
MX2024009854A MX2024009854A MX2024009854A MX2024009854A MX 2024009854 A MX2024009854 A MX 2024009854A MX 2024009854 A MX2024009854 A MX 2024009854A MX 2024009854 A MX2024009854 A MX 2024009854A MX 2024009854 A MX2024009854 A MX 2024009854A
Authority
MX
Mexico
Prior art keywords
rare genetic
obesity
agonist
treat
prevent
Prior art date
Application number
MX2024009854A
Other languages
English (en)
Spanish (es)
Inventor
Hee Dong Park
Hye Kyeong Hwang
Su Jin Yeo
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2024009854A publication Critical patent/MX2024009854A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024009854A 2022-02-08 2024-08-12 Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genetica rara de la obesidad MX2024009854A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20220016377 2022-02-08
PCT/KR2023/001712 WO2023153762A1 (ko) 2022-02-08 2023-02-07 멜라노코르틴-4 수용체 효능제의 희귀성 유전적 비만질환의 예방 또는 치료에서의 용도

Publications (1)

Publication Number Publication Date
MX2024009854A true MX2024009854A (es) 2024-11-08

Family

ID=87564659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009854A MX2024009854A (es) 2022-02-08 2024-08-12 Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genetica rara de la obesidad

Country Status (13)

Country Link
US (1) US20250134898A1 (cg-RX-API-DMAC7.html)
EP (1) EP4461297A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505229A (cg-RX-API-DMAC7.html)
KR (1) KR20230120106A (cg-RX-API-DMAC7.html)
CN (1) CN119300835A (cg-RX-API-DMAC7.html)
AR (1) AR128463A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023218785A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248118A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002389A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024011882A2 (cg-RX-API-DMAC7.html)
MX (1) MX2024009854A (cg-RX-API-DMAC7.html)
TW (1) TWI838114B (cg-RX-API-DMAC7.html)
WO (1) WO2023153762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3202315A1 (en) * 2020-12-22 2022-06-30 Hee Dong Park Use as selective agonist of malanocortin-4 receptor
KR20250046623A (ko) * 2023-09-27 2025-04-03 주식회사 엘지화학 멜라노코르틴-4 수용체 효능제의 pcsk1 결핍 적응증과 연관된 희귀성 유전적 비만질환의 예방 또는 치료 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
US12516047B2 (en) * 2019-11-07 2026-01-06 Lg Chem, Ltd. Melanocortin-4 receptor agonists
CN116507615A (zh) * 2020-10-29 2023-07-28 株式会社Lg化学 黑皮质素受体激动剂化合物的晶型i及其制备方法
TWI804170B (zh) * 2021-01-21 2023-06-01 南韓商Lg化學股份有限公司 黑皮質素-4受體促效劑的用途
TWI826938B (zh) * 2021-02-26 2023-12-21 南韓商Lg化學股份有限公司 黑皮質素-4受體促效劑
TWI861780B (zh) * 2022-03-28 2024-11-11 南韓商Lg化學股份有限公司 預防或治療肥胖的聯合療法

Also Published As

Publication number Publication date
JP2025505229A (ja) 2025-02-21
AU2023218785A1 (en) 2024-08-22
CA3248118A1 (en) 2025-01-24
WO2023153762A1 (ko) 2023-08-17
EP4461297A4 (en) 2025-04-09
CL2024002389A1 (es) 2025-01-31
TW202339761A (zh) 2023-10-16
CN119300835A (zh) 2025-01-10
AR128463A1 (es) 2024-05-08
CO2024011882A2 (es) 2025-01-23
TWI838114B (zh) 2024-04-01
EP4461297A1 (en) 2024-11-13
US20250134898A1 (en) 2025-05-01
KR20230120106A (ko) 2023-08-16

Similar Documents

Publication Publication Date Title
CO2024011882A2 (es) Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genética rara de la obesidad
Yang et al. MiR-155 aggravated septic liver injury by oxidative stress-mediated ER stress and mitochondrial dysfunction via targeting Nrf-2
Vanlangenakker et al. Molecular mechanisms and pathophysiology of necrotic cell death
Yu et al. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells
AU2025283528A1 (en) Methods of treating WHSC1-overexpressing cancers by inhibiting SETD2
CN115192719B (zh) 用于治疗肺血管疾病的组合物和方法
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
JOP20220056A1 (ar) مركبات rip1 تثبيطية وطرق عملها واستخدامها
ECSP088218A (es) Bencimidazoles sustituidos como inhibidores de cinasa
GT200500158A (es) Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa
MX2023008098A (es) Uso de agonista del receptor de melanocortina-4.
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
NZ598778A (en) Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
Yeh et al. Lercanidipine and labedipinedilol-A attenuate lipopolysaccharide/interferon-γ-induced inflammation in rat vascular smooth muscle cells through inhibition of HMGB1 release and MMP-2, 9 activities
SV2007002146A (es) Difenilimidazopirimidina e imidazol aminas como inhibidores de beta-secretasa ref. am101727
CL2012001349A1 (es) Uso de una composicion farmaceutica que comprende telmisartan para el tratamiento de hipertension sistemica en gatos ( div. sol. 2897-07).
MX2018011349A (es) Uso de masitinib para el tratamiento de una subpoblacion de pacientes con esclerosis lateral amiotrofica.
CL2008001238A1 (es) Anticuerpo antagonista aislado anti-receptor grig/pro362/jam4/stigma murino con numero de deposito atcc pat-8298; composicion farmaceutica; uso medico para inhibir la entrada celulst dependiente del complemento mediada por crig de un patogeno intracelular (pi), o para prevenir o tratar una enfermedadad infeccionsa mediada por un pi
Chen et al. Promoter methylation of Egr-1 site contributes to fetal hypoxia-mediated PKCε gene repression in the developing heart
Serlin et al. Interleukin‐1β induces osteopontin expression in pulmonary fibroblasts
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
KR20180071722A (ko) Glutathione, Thioredoxin, Nrf2 항산화계 병합억제를 통한 선택적 암세포사멸 유도
Ghassemifar et al. MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells
GT200600160A (es) Tratamiento del dolor
Dong et al. Quercetin improves macrophage immune regulatory functions to alleviate airway Th2 polarization